Key facts
- RxAnte’s last known valuation is $28.9M (Nov 2020).
- It has raised $49.8M across 1 recorded rounds; the latest was PE Growth/Expansion in Dec 2025.
- Notable investors include First Trust Capital Partners, PNC Erieview Capital, Primus Capital, Trinity Capital (Phoenix).
- RxAnte has filed 2 Form Ds with the SEC since 2020, most recently May 2022 ($10.9M sold to 7 investors).
- Status: Acquired/Merged (Operating Subsidiary).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for RxAnte
Funding rounds
1 roundsAbout RxAnte
Provider of predictive analytics and targeted clinical programs intended to improve medication prescribing and adherence. The company's platform specializes in providing high-value pharmacy services and improving medication prescribing, adherence, clinical quality scores, and total cost of care, enabling clients with a good pharmacy experience while working with their prescribers and caregivers to make regimens safer, simpler, and more affordable.
- Sector
- Healthcare
- HQ
- Portland, ME, United States
- Founded
- 2011
- Employees
- 95
- Website
- rxante.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
RxAnte doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RxAnte shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RxAnte in its N-PORT filings yet. We sweep new filings monthly.